2022 Nuclear Medicine & Molecular Imaging News

"The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence. The institutions are designated as comprehensive centers that administer multiple radiopharmaceutical therapies — such as those to treat thyroid cancer, prostate cancer and neuroendocrine tumors—and activelyengage in radiopharmaceutical therapy research.

SNMMI created the Radiopharmaceutical Therapy Center of Excellence program to certify sites that meet strict regulatory, training, qualification, experience and performance criteria for radiopharmaceutical therapy. With the Radiopharmaceutical Therapy Centers of Excellence designation, institutions can assure patients, their families, referring physicians and payors that rigorous procedures are in place and followed, ultimately leading to appropriate patient selection and optimal outcomes from radiopharmaceutical therapy."